

Let's Bump Up The Boosters!

Did you know that even if you've been fully vaccinated against COVID-19 (two doses), your protection against the virus may decrease over time? That's why doctors and the CDC are recommending everyone ages 6 months and over receive the Omicron Bivalent booster shot, about two months after their initial series of vaccinations or after a previous booster shot.



Why Boost?

COVID-19 vaccine boosters can further enhance or restore protection that might have decreased over time after your primary vaccination series. People are protected best from severe COVID-19 illness when they stay up to date with their COVID-19 vaccines, which includes getting all recommended boosters when eligible.

When to Boost?

COVID-19 vaccine boosters can further enhance or restore protection that might have decreased over time after your primary vaccination series. People are protected best from severe COVID-19 illness when they stay up to date with their COVID-19 vaccines, which includes getting all recommended boosters when eligible.

Who Can Get A Booster

As of December 14th, 2022, in addition to all adults, children ages 6 months and up are recommended to get an Omicron Bivalent Booster at least 2 months after 2nd primary series dose.

Find out more information at <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html>

The FDA has authorized the updated (bivalent) Moderna and Pfizer-BioNTech COVID-19 vaccines to include use for children 6 months of age and up.

Authorized Use

Emergency uses of the vaccines have been approved or licensed by the FDA under the Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19). The Moderna COVID-19 Vaccine is authorized in individuals 6 months of age and older as a primary series. The Moderna COVID-19 Vaccine, Bivalent is authorized as a booster dose in individuals 6 years of age and older.

The FDA decision is based on the totality of the scientific evidence available showing that the product may be effective to prevent COVID-19 during the COVID-19 pandemic and that the known and potential benefits of the product outweigh the known and potential risks of the product.